Australia markets closed

Nuvectis Pharma, Inc. (NVCT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
13.94+0.26 (+1.90%)
At close: 04:00PM EDT
13.94 0.00 (0.00%)
After hours: 04:02PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 240.20M
Enterprise value 215.60M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)11.81
Enterprise value/revenue N/A
Enterprise value/EBITDA -9.54

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 377.82%
S&P500 52-week change 318.47%
52-week high 318.65
52-week low 36.21
50-day moving average 314.43
200-day moving average 312.95

Share statistics

Avg vol (3-month) 342.51k
Avg vol (10-day) 376.07k
Shares outstanding 517.23M
Implied shares outstanding 617.23M
Float 84.23M
% held by insiders 160.34%
% held by institutions 115.00%
Shares short (30 Aug 2023) 4172.95k
Short ratio (30 Aug 2023) 44.91
Short % of float (30 Aug 2023) 41.99%
Short % of shares outstanding (30 Aug 2023) 41.00%
Shares short (prior month 30 July 2023) 4317.26k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 June 2023


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-68.24%
Return on equity (ttm)-140.30%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
Net income avi to common (ttm)-22.33M
Diluted EPS (ttm)-1.51
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)24.6M
Total cash per share (mrq)1.43
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)5.41
Book value per share (mrq)1.18

Cash flow statement

Operating cash flow (ttm)-16.8M
Levered free cash flow (ttm)-7.77M